Ionis Pharmaceuticals (IONS) Misses Q3 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Wall St set for steady open as oil jumps ahead of key earnings
- Oil prices rise as attacks on Saudi Arabia overshadow Trump's Russian supply announcements
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- Iren shares jump 5% in premarket trade on report of Anthropic AI cloud deal
- One dead in new attack on Saudi airport, a day after Houthi strike kills 13
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Stryker invests $400M in CMR Surgical with option to acquire
- Enovix posts $11M in Q3 revenue, beats guidance by 10%
- Deutsche Bank Upgrades AST Spacemobile (ASTS) to Buy
Ionis Pharmaceuticals (IONS) PT Lowered to $60 at Needham & Company
November 4, 2021 7:28 AM EDTNeedham & Company analyst Chad Messer lowered the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $60.00 (from $84.00) while maintaining a Buy rating.
The analyst commented, "IONS reported 3Q21 financial results yesterday, and we spoke w/ mgmt for additional details. Partner BIIB (not rated) previously... More



